Summary
Regeneron Pharmaceuticals, Inc. filed this Form 8-K on January 12, 2016, to announce upcoming presentations at the 34th Annual J.P. Morgan Healthcare Conference. The primary focus for investors is the expected disclosure of preliminary full-year 2015 U.S. and global net sales for their key drug, EYLEA® (aflibercept). These presentations, scheduled for January 13, 2016, will feature updates from Regeneron's CEO, Dr. Leonard S. Schleifer, and CFO, Robert E. Landry. The market will be closely watching these figures to gauge EYLEA's commercial performance and its contribution to the company's overall financial health heading into 2016. The filing also notes that the information provided in these presentations will not be deemed "filed" for SEC purposes, meaning it's a voluntary update.
Key Highlights
- 1Regeneron will provide preliminary full-year 2015 U.S. net sales for EYLEA® at the J.P. Morgan Healthcare Conference.
- 2Preliminary global net sales for EYLEA® for the full year 2015 will also be disclosed.
- 3The company's CEO and CFO will be presenting updates on January 13, 2016.
- 4The filing includes furnished presentations as exhibits, offering detailed insights into EYLEA sales and a 2016 financial overview.
- 5This report serves as a communication vehicle for investor updates during a major industry conference.
- 6Information presented is furnished and not deemed 'filed' under Section 18 of the Exchange Act.